Therapeutic Effects Of Aspirin Combined With Atorvastatin On Ischemic Strokes
Zhongbo Zhang,Xinzhe Yao,Minghua Wang,Yudiao Huang,Tong Shen,Weinan Zhang,Yingying Liu
2018-01-01
Abstract:Objective: The aim of this study was to investigate the efficacy of aspirin combined with atorvastatin in the treatment of ischemic stroke. Methods: A total of 127 patients with ischemic strokes, admitted to The Fifth Affiliated Hospital, Harbin Medical University, from January 2016 to December 2017, were randomly divided into an observation group (n=66) and control group (n=61). In the control group, patients were treated with aspirin alone. Patients in the observation group were treated with aspirin combined with atorvastatin. Oxidized low-density lipoprotein (OX-LDL), transforming growth factor-beta 1 (TGF-beta 1), vascular cell adhesion molecule-1 (VCAM-1), high-sensitivity C-reactive protein (hs-CRP), and lipid levels in serum were measured before treatment and at 6 months after treatment. Modified RANKIN scale (mRS) scores, modified Barthel index (MBI) scores, carotid intimal plaque area, and carotid intima-media thickness were compared before treatment and 6 months after treatment for the two groups. Recurrence rates of ischemic strokes, incidence of cerebrovascular disease, and incidence of adverse reactions were compared between the two groups. Results: After 6 months of treatment, levels of OX-LDL, VCAM-1, hs-CRP, total cholesterol, low-density lipoprotein cholesterol, and triglycerides in serum in the observation group were significantly lower than those before treatment (all P < 0.05). Levels of serum TGF-beta 1 and high-density lipoprotein cholesterol were significantly higher than those before treatment (both P < 0.05). Serum levels of OX-LDL, TGF-beta 1, hs-CRP, VCAM-1, and lipids were not significantly different before and after treatment in the control group as well as between the two groups before treatment (all P > 0.05). However, there were significant differences in serum levels of the above five indicators between the two groups at 6 months after treatment (all P < 0.05). There were no significant differences in mRS scores, MBI scores, carotid intimal plaque area, and carotid intima-media thickness between the two groups before treatment (all P > 0.05). After 6 months of treatment, mRS scores of the observation group were significantly lower than that of the control group. MBI scores were significantly higher than that of the control group. Carotid intimal plaque area and carotid intima-media thickness were both less than those of the control group. Differences were statistically significant (all P < 0.05). Recurrence rate of ischemic stroke and incidence of cerebrovascular disease in the observation group were significantly lower than those in the control group (both P < 0.05). There were no significant differences in incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Aspirin combined with atorvastatin has synergistic effects in the treatment of ischemic stroke. It has significant effects on regulating lipids, improving atherosclerotic plaque, and improving quality of life. It is also safe and worthy of clinical application.